martes, 31 de diciembre de 2019

Clinical Trials Update from NCI, December 2019

Clinical Trials Update from NCI, December 2019

National Cancer Institute banner

Clinical Trials
Updates from the National Cancer Institute
Clinical Trials News
A structural illustration showing osimertinib binding to the EGFR protein. Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations

Osimertinib (Tagrisso) improves survival in people with non-small cell lung cancer with EGFR mutations, updated clinical trial results show. People treated with osimertinib lived longer than those treated with earlier generation EGFR-targeted drugs.
Photo of surgeons operating on patient. Surgery for Recurrent Ovarian Cancer Does Not Improve Survival

Secondary surgery for women with recurrent ovarian cancer does not improve how long those women live, findings from a large clinical trial show. The results call into question the current standard practice for these patients.
Immunotherapy Drug Improves Outcomes for Some Children with Relapsed Leukemia

New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab (Blincyto) is better than standard chemotherapy for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned after treatment.
RAS oncogene factoid Overcoming a Cancer Nemesis? KRAS Inhibitor Shows Promise in Early Trial

An experimental drug, AMG 510, that targets mutated forms of the KRAS protein completely shrank tumors in mouse models of human cancer. And data from a small clinical trial show that AMG 510 appears to be active against different cancer types with a KRAS mutation.
Gilteritinib Improves Survival in AML with FLT3 Mutations

People with relapsed or refractory acute myeloid leukemia (AML) with FLT3 gene mutations who were treated with gilteritinib (Xospata) had improved survival, higher rates of remission, and fewer side effects than those treated with chemotherapy, a recent clinical trial found.
Clinical Trials Information for Patients and Caregivers
Where Trials Take Place

Clinical trials may be closer to you than you think. Cancer clinical trials take place in cities and towns all across the United States. Ask your health care provider about clinical trials near you, or use NCI’s clinical trials search form to search for trials within a set distance from your ZIP code.
Types of Clinical Trials

Types of cancer clinical trials include treatment trials, prevention trials, screening trials, and supportive and palliative care trials. Each type of trial is designed to answer different research questions and will help researchers learn things that will help people in the future.
Clinical trials search Find NCI-Supported Clinical Trials

Use our search form to find a clinical trial or other research study that may be right for you or a loved one.
NCI-Supported Clinical Trials That Are Recruiting Patients 
Comparing Treatments for Residual Triple Negative Breast Cancer

This phase 3 trial is comparing post-operative intravenous platinum-based chemotherapy with oral capecitabine (Xeloda) for patients with residual triple negative breast cancer following neoadjuvant therapy. The study will help determine if one treatment is better than the other at preventing the disease from coming back.
Three-Drug Combination for Older Patients with Chronic Lymphocytic Leukemia

This phase 3 trial is comparing standard therapy of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) with a three-drug combination of ibrutinib, obinutuzumab, and venetoclax (Venclexta) for patients aged 70 or older with untreated chronic lymphocytic leukemia. The study will help determine if the addition of venetoclax improves progression-free survivalcomplete response rate, and overall survival.
Standard Systemic Therapy Plus Surgery or Radiotherapy for Metastatic Prostate Cancer

This phase 3 trial will test whether adding definitive radiation therapy or surgical removal of the primary tumor to standard systemic therapy will help men with metastatic prostate cancer live longer. Doctors also want to see if adding localized treatment to systemic therapy improves the quality of life for these patients and slows progression of the disease.

No hay comentarios:

Publicar un comentario